New combo attack on rectal cancer: chemo plus targeted surgery shows promise
NCT ID NCT06048146
First seen Apr 08, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This study looked at 180 people with rectal cancer that had spread to lymph nodes in the pelvis. One group received a three-drug chemotherapy regimen (FOLFOXIRI) followed by surgery to remove the affected lymph nodes. The other group got standard chemoradiotherapy before surgery. The goal was to see if the new approach improves how long people live without the cancer coming back. The trial is complete, and results will help determine if this more intensive treatment is worth the extra side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FOLFOXIRI (irinotecan, oxaliplatin, 5-fluorouracil) and lateral lymph node dissection
What this could lead to
If successful, this approach could improve survival and reduce cancer recurrence for people with rectal cancer that has spread to nearby lymph nodes.
What could go wrong
This is a completed study with 180 participants, but results are not yet widely confirmed. The three-drug chemo regimen has higher side effects, and the surgery adds risks. Further research is needed to see if it truly beats standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.